National Institute of Allergy and Infectious Diseases (NIAID) News

A new report from various organizations under the National Institutes of Health details the clinical course of a 34-year-old American with Ebola virus disease who received intensive supportive care through a clinical trial at the NIH Special Clinical Studies Unit.
Read More »

Purdue University researchers recently created a near-atomic level map of the Zika virus, which could spark vaccines, antiviral drugs, antibodies and a diagnostic test capable of differentiating Zika virus infections from dengue infections.
Read More »

The National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health, recently released a statement verifying the organization’s commitment to researching, preventing and treating tuberculosis.
Read More »

A new study from the South African Tuberculosis Vaccine Initiative at the University of Cape Town suggests that a simple blood test can predict a person’s chances of developing tuberculosis.
Read More »

A clinical trial designed to compare three advanced Kaposi’s sarcoma chemotherapy treatment regimens combined with antiretroviral treatment for AIDS patients will not accept any more participants into its oral chemotherapy drug etoposide tests.
Read More »

All of the subjects who participated in a clinical trial for an experimental dengue virus vaccine showed vastly different results, as the 21 vaccine recipients did not develop the dengue infection, but the 20 placebo recipients did contract the infection.
Read More »

A team of scientists at the University of Vermont (UVM) Vaccine Testing Center has been working to develop an efficient, single-dose vaccine designed to protect people from the four strains of dengue fever, and the team said this week that clinical trials on a test vaccine have been promising so far.
Read More »

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), will proceed with the HIV Open-label Prevention Extension (HOPE) Phase 3B trial to study the use of a dapivirine vaginal ring to prevent HIV in women.
Read More »

Researchers from the National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health, recently developed an antibody that protects monkeys from developing Ebola infections.
Read More »

ZMapp, an experimental treatment for the Ebola virus, may be beneficial to Ebola patients but there is still a lack of data from its developer, Mapp Biopharmaceutical Inc., to determine whether it can be used to treat humans.
Read More »

Scientists from the National Institutes of Allergy and Infectious Diseases recently conducted a study demonstrating that ongoing HIV replication continues even during antiretroviral therapy (ART) treatments.
Read More »

The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health, recently released a slideshow that emphasizes the notable scientific progress that NIAID researchers have accomplished for 2015.
Read More »

National Institutes of Health (NIH) researchers at the National Institute of Allergy and Infectious Diseases (NIAID) recently used three clinical studies to create guidelines for preventing and treating HIV infections.
Read More »

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), have used evidence from three large clinical trials to develop a blueprint of prevention and treatment for HIV infections.
Read More »